Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sm pharmaceuticals sdn. bhd. - frusemide/furosemide -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; propyl hydroxybenzoate; povidone; colloidal anhydrous silica; sodium starch glycollate; butyl hydroxybenzoate - oedema: adults and children. treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by intravenous or intramuscular route. parenteral use should be replaced with oral frusemide ascent as soon as practical. hypertension: adults. oral frusemide ascent may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide ascent alone.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - furosemide, quantity: 20 mg - tablet, uncoated - excipient ingredients: propyl hydroxybenzoate; lactose monohydrate; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; butyl hydroxybenzoate; colloidal anhydrous silica; povidone - oedema: adults and children. treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by intravenous or intramuscular route. parenteral use should be replaced with oral frusemide ascent as soon as practical. hypertension: adults. oral frusemide ascent may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide ascent alone.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; butyl hydroxybenzoate; sodium starch glycollate; colloidal anhydrous silica; propyl hydroxybenzoate; povidone; lactose monohydrate - oedema: adults and children. treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by intravenous or intramuscular route. parenteral use should be replaced with oral frusemide-ga as soon as practical. hypertension: adults. oral frusemide-ga may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide-ga alone.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - furosemide, quantity: 20 mg - tablet, uncoated - excipient ingredients: butyl hydroxybenzoate; colloidal anhydrous silica; propyl hydroxybenzoate; magnesium stearate; povidone; sodium starch glycollate; microcrystalline cellulose; lactose monohydrate - oedema: adults and children. treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by intravenous or intramuscular route. parenteral use should be replaced with oral frusemide-ga as soon as practical. hypertension: adults. oral frusemide-ga may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide-ga alone.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metformin hydrochloride, quantity: 500 mg; saxagliptin, quantity: 5 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; carmellose sodium; hypromellose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; saxagliptin, quantity: 5 mg - tablet, modified release - excipient ingredients: hypromellose; carmellose sodium; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; saxagliptin, quantity: 2.5 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; carmellose sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid; iron oxide yellow - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty 50 mg); metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; triethyl citrate; hyprolose; povidone; hypromellose; purified talc; titanium dioxide; microcrystalline cellulose; sodium lauryl sulfate; sodium stearylfumarate; iron oxide red - sitagliptin/metformin sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.